Frequently Asked Questions

Answers to the questions researchers contact us about most often, all in one place.

---

🛡 Are products independently tested?

Janoshik HPLC verification on every batch

Yes. Every batch undergoes independent HPLC testing.

All Tesamorelin supplied is analysed by Janoshik Analytical, an independent peptide-analysis laboratory based in the Czech Republic. Reported purity consistently exceeds 99%.

When a Janoshik report is available for the current production batch, a printed Certificate of Analysis (COA) is included with the order. If a report is not included, the batch verification record is published on our Purity page.

Each COA contains a unique verification code that can be validated through Janoshik’s own verification platform, allowing researchers to confirm testing results independently.

---

💧 Reconstitution Guide

Mixing bacteriostatic water with lyophilised powder

Four preparation steps:

1. Clean the vial stopper
Use an alcohol prep wipe supplied with the kit and allow the stopper to dry.

2. Draw bacteriostatic water
Using an insulin syringe, draw 2 mL of BAC water.

3. Add the diluent slowly
Inject the BAC water gradually along the inside wall of the vial. Avoid directing the liquid directly onto the powder.

4. Dissolve gently
Carefully swirl until fully dissolved. Do not shake. Allow approximately 30 seconds before refrigeration.

For future preparation, refer to the reconstitution guide included inside the box.

---

💉 Pen Guide

Dose dial, priming and preparation

Preparing the pen

Attach a new needle
Clean the pen tip with an alcohol wipe, then attach a fresh sterile needle.

Prime the pen
Dial one click, hold the pen upright with the needle facing upward, and press the dose button. A small droplet appearing at the needle tip confirms priming and removal of air.

Select the research setting
Each dial click represents a fixed increment depending on the pen calibration. The display window indicates the total selected amount.

Example: a 6 mg research setting may correspond to approximately 6–12 clicks depending on calibration.

Follow routes described in published research
Published study protocols describe subcutaneous administration sites including the abdomen, thigh, and upper arm.

After use

• Dispose of the needle safely in a sharps container.
• Replace the pen cap.
• Return the pen to refrigerated storage.

Each pen provides the number of uses listed for the selected size. Once depleted, replace the cartridge while continuing to use the same pen body.

Research use only. Procedures are based on published research protocols and do not represent medical or human-use guidance.

---

❄ Storage Information

Lyophilised Tesamorelin

• Store sealed at 2–8°C
• Protect from light
• Do not freeze
• Stable for 24+ months under recommended conditions

Reconstituted Solution

• Store at 2–8°C
• Keep in the original glass vial
• Avoid shaking
• Discard if cloudy or discoloured

BAC Water

• Refrigerate after opening
• Use within approximately 30 days

---

📍 Administration Information

Route described in published research

Published Tesamorelin research describes subcutaneous administration routes, including areas such as the abdomen, thigh, and upper arm, within pharmacokinetic and clinical research settings.

Research protocols commonly rotate administration sites to minimise repeated local tissue stress.

This information is provided only as scientific context from peer-reviewed literature. We do not provide medical advice, dosing instructions, or human-use protocols.

Reference: Falutz et al. 2010

---

🎯 Research Protocol Information

What amount should researchers use?

The appropriate approach is to follow the research protocol framework relevant to the study design.

Published Tesamorelin research commonly evaluates structured progression through study phases, beginning with lower research stages before moving to later stages.

New researchers

Researchers beginning work with this compound typically review the initial study phase before progressing through subsequent protocol stages.

Experienced researchers

Researchers familiar with Tesamorelin can review protocol information to determine suitable research requirements and compare available formats.

Custom research requirements

For non-standard laboratory schedules, contact our team before ordering. We can help identify the most suitable vial size or format based on planned research requirements.

Research use only. Information is derived from peer-reviewed literature and does not constitute medical guidance.

---

Key Information

Specification	Details
Compound	Tesamorelin
Research Category	GHRH / Secretagogue Research
Available Sizes	2 mg, 5 mg, 10 mg, 20 mg
Pricing	From £69
Format	Lyophilised powder vial and pre-reconstituted pen
Purity	>99% HPLC verified by Janoshik Analytical
Intended Use	In-vitro laboratory research only

---

Chemical & Reference Data

Information compiled from public databases and peer-reviewed scientific literature for research characterisation.

Property	Details
Compound Class	Synthetic GHRH(1-44) analogue with N-terminal hexenoyl modification
Molecular Formula	C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight	5135.9 g/mol
CAS Number	218949-48-5
PubChem CID	16133824
Residue Count	44 amino acids
Sequence	trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH₂
Receptor Profile	GHRH receptor agonist (GHRH 1–44 fragment)
Reported Half-life	Approximately 25–40 minutes in human serum
Solubility	Reconstitutes in bacteriostatic water for laboratory use
Lyophilised Storage	2–8°C, stable for 24+ months
Reconstituted Storage	Refrigerated storage recommended
Regulatory Status	FDA-approved in 2010 for HIV-associated lipodystrophy applications

---

Research Profile

• 44-amino-acid GHRH analogue
• N-terminal hexenoyl modification
• Designed to improve resistance to protease degradation
• Third-party purity tested
• Laboratory research use only

Tesamorelin is a synthetic peptide based on the 44-amino-acid growth hormone-releasing hormone (GHRH) sequence with an N-terminal trans-3-hexenoyl modification.

It is supplied as a lyophilised powder intended exclusively for laboratory research.

The information above describes how Tesamorelin is characterised in published scientific literature and does not represent claims regarding effects in humans.

---

Laboratory Handling

Tesamorelin is supplied as a freeze-dried powder in a sealed glass vial.

For laboratory preparation:

• Add the required diluent slowly along the vial wall.
• Swirl gently until dissolved.
• Do not vortex or shake.
• Store prepared solutions at 2–8°C.

A reconstitution calculator can be used to determine the final concentration (mg/mL).

State	Temperature	Typical Stability
Lyophilised	2–8°C or -20°C	Up to 24 months
Reconstituted	2–8°C	Approximately 4–6 weeks

---

Purity & Verification

Every Tesamorelin batch undergoes independent HPLC verification by Janoshik Analytical.

Where available, the batch Certificate of Analysis includes a unique verification key that can be authenticated against Janoshik records.

Reported purity consistently exceeds 99%.

---

Related Research Compounds

Researchers studying Tesamorelin may also explore:

• Sermorelin – GHRH / Secretagogue Research
• CJC-1295 (with DAC) – GHRH / Secretagogue Research
• Ipamorelin – GHRH / Secretagogue Research

---

Key Literature Reference

Falutz J. et al.
Effects of Tesamorelin (TH9507) – Phase 3 Study.
New England Journal of Medicine (2007). PMID: 20071701

References are independent peer-reviewed publications. Vantix Bio is not affiliated with these studies or their authors.